{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T04:13:02Z","timestamp":1782879182320,"version":"3.54.5"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"32","license":[{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,8,12]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Patients with rectal gastrointestinal stromal tumors (GISTs) who achieve a complete response (CR) with imatinib therapy have rarely been reported in the literature. Moreover, no treatment guidelines have been established for rectal GIST patients with CR after imatinib treatment, warranting further studies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 51-year-old man presented to our outpatient clinic in October 2013 with complaints of difficulty to defecate and a change in stool characteristics. During digital rectal examination, a mass was palpated within 5\u2009cm from the anal verge. Contrast-enhanced computed tomography revealed a 8.1\u2009\u00d7\u20097.2-cm rectal mass with significant enhancement during the arterial phase.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>A diagnosis of GIST was established after conducting needle biopsy and immunohistochemistry staining.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Imatinib therapy (400\u2009mg\/d, oral administration) was immediately started. When the patient achieved clinical CR (cCR), the oncologist recommended the patient to continue imatinib treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>At 7 months after imatinib administration, the patient achieved cCR. As suggested by the oncologist, the patient continued to receive imatinib treatment after cCR. After 13 months, the patient spontaneously stopped imatinib. Finally, tumor recurrence was observed 7 months later.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Surgery remains the mainstay of treatment for advanced rectal GIST patients who achieve cCR after imatinib treatment. Close follow-up and continuous imatinib treatment are indicated in patients who cannot undergo surgery.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000029411","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T14:10:38Z","timestamp":1660313438000},"page":"e29411","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Complete response of advanced rectal gastrointestinal stromal tumors after imatinib treatment: A case report and literature review"],"prefix":"10.1097","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5006-0146","authenticated-orcid":false,"given":"Tingting","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Colorectal Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, People\u2019s Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobin","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, People\u2019s Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, People\u2019s Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/nrc3143","article-title":"Gastrointestinal stromal tumours: origin and molecular oncology.","volume":"11","author":"Corless","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1126\/science.279.5350.577","article-title":"Gain-of-function mutations of c-KIT in human gastrointestinal stromal tumors.","volume":"279","author":"Hirota","year":"1998","journal-title":"Science"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0016-5085(03)01046-1","article-title":"Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.","volume":"125","author":"Hirota","year":"2003","journal-title":"Gastroenterology"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1097\/00000478-200109000-00002","article-title":"Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: a clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases.","volume":"25","author":"Miettinen","year":"2001","journal-title":"Am J Surg Pathol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s11605-012-2086-0","article-title":"Clinicopathological features and prognostic factors of rectal gastrointestinal stromal tumors.","volume":"17","author":"Xiao","year":"2013","journal-title":"J Gastrointest Surg"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00000658-200001000-00008","article-title":"Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.","volume":"231","author":"DeMatteo","year":"2000","journal-title":"Ann Surg"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.4081\/rt.2011.e35","article-title":"Radiotherapy in the treatment of gastrointestinal stromal tumor.","volume":"3","author":"Knowlton","year":"2011","journal-title":"Rare Tumors"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1111\/apt.12761","article-title":"Review article: the biology, diagnosis and management of gastrointestinal stromal tumours.","volume":"39","author":"Iorio","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1136\/gut.2005.086744","article-title":"First report of a complete pathological response of a pelvic GIST treated with imatinib as neoadjuvant therapy.","volume":"55","author":"Salazar","year":"2006","journal-title":"Gut"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.3748\/wjg.15.1910","article-title":"Imatinib mesylate neoadjuvant treatment for rectal malignant gastrointestinal stromal tumor.","volume":"15","author":"Hou","year":"2009","journal-title":"World J Gastroenterol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10147-010-0133-y","article-title":"Pathologic complete response with neoadjuvant imatinib for locally advanced pelvic GIST.","volume":"16","author":"de Azevedo","year":"2011","journal-title":"Int J Clin Oncol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/01.meg.0000230087.83792.1f","article-title":"Neoadjuvant imatinib in a locally advanced gastrointestinal stromal tumour (GIST) of the rectum: a rare case of two GISTs within a family without a familial GIST syndrome.","volume":"19","author":"Mandala","year":"2007","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1177\/030089160909500217","article-title":"Molecularly targeted therapy and radiotherapy in the management of localized gastrointestinal stromal tumor (GIST) of the rectum: a case report.","volume":"95","author":"Ciresa","year":"2009","journal-title":"Tumori"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1097\/01.pas.0000209847.59670.c8","article-title":"Gastrointestinal stromal tumors (GISTs) on prostate needle biopsy: a clinicopathologic study of 8 cases.","volume":"30","author":"Herawi","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1111\/j.1463-1318.2010.02442.x","article-title":"The effect of neoadjuvant imatinib therapy on outcome and survival after rectal gastrointestinal stromal tumour.","volume":"13","author":"Machlenkin","year":"2011","journal-title":"Colorectal Dis"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-update and clarification: from the RECIST committee.","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.3892\/etm.2015.2613","article-title":"Analysis of mutation of the c-KIT gene and PDGFRA in gastrointestinal stromal tumors.","volume":"10","author":"Xu","year":"2015","journal-title":"Exp Ther Med"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2017.74.9705","article-title":"Gastrointestinal stromal tumors.","volume":"36","author":"von Mehren","year":"2018","journal-title":"J Clin Oncol"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0140-6736(04)17098-0","article-title":"Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.","volume":"364","author":"Verweij","year":"2004","journal-title":"Lancet"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1200\/JCO.2007.13.4452","article-title":"Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.","volume":"26","author":"Blanke","year":"2008","journal-title":"J Clin Oncol"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1200\/JCO.2009.24.2099","article-title":"Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients.","volume":"28","year":"2010","journal-title":"J Clin Oncol: Official J Am Soc Clin Oncol"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/13543784.2021.1857363","article-title":"Systemic therapy of advanced\/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib.","volume":"30","author":"Mohammadi","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"issue":"suppl 2","key":"R23-20250504","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1634\/theoncologist.13-S2-4","article-title":"Response evaluation of gastrointestinal stromal tumors.","volume":"13","author":"Choi","year":"2008","journal-title":"The Oncologist"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1245\/s10434-006-9034-8","article-title":"Surgical resection of gastrointestinal stromal tumors after treatment with imatinib.","volume":"14","author":"Andtbacka","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"6800","DOI":"10.1200\/JCO.2005.02.1063","article-title":"Complete remission with imatinib in metastastic gastrointestinal stromal tumors.","volume":"23","author":"Bauer","year":"2005","journal-title":"Journal of Clin Oncol: Official J Am Soc Clin Oncol"},{"key":"R26-20250504","first-page":"815","article-title":"Continuous v.s. intermittent imatinib treatment in advanced GIST after one year: a prospective randomized phase III trial of the French Sarcoma Group.","volume":"23","author":"Blay","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"951","DOI":"10.6004\/jnccn.2012.0099","article-title":"Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines.","volume":"10","author":"von Mehren","year":"2012","journal-title":"J Natl Compr Canc Netw: JNCCN"},{"issue":"suppl 2","key":"R28-20250504","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2010.0116","article-title":"NCCN task force report: update on the management of patients with gastrointestinal stromal tumors.","volume":"8","author":"Demetri","year":"2010","journal-title":"J Natl Compr Canc Netw"},{"key":"R29-20250504","first-page":"975","article-title":"A case of recurrent gastrointestinal stromal tumor of the stomach with complete response to imatinib mesilate.","volume":"36","author":"Aoyama","year":"2009","journal-title":"Gan To Kagaku Ryoho"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1055\/s-2008-1027243","article-title":"Surgical management and clinical outcome of gastrointestinal stromal tumor of the colon and rectum.","volume":"46","author":"Chen","year":"2008","journal-title":"Z Gastroenterol"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"201","DOI":"10.21037\/atm.2020.01.55","article-title":"Transanal versus nontransanal surgery for the treatment of primary rectal gastrointestinal stromal tumors: a 10-year experience in a high-volume center.","volume":"8","author":"Yang","year":"2020","journal-title":"Ann Transl Med"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"e7538","DOI":"10.1097\/MD.0000000000007538","article-title":"Initial application of transanal endoscopic microsurgery for high-risk lower rectal gastrointestinal stromal tumor after imatinib mesylate neoadjuvant chemotherapy: a case report.","volume":"96","author":"Liu","year":"2017","journal-title":"Medicine (Baltim)"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1089\/lap.2017.0051","article-title":"A novel curative treatment strategy for patients with lower grade rectal gastrointestinal stromal tumor: chemoreduction combined with transanal endoscopic microsurgery.","volume":"27","author":"Han","year":"2017","journal-title":"J Laparoendosc Adv Surg Tech A"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/jama.2012.347","article-title":"One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.","volume":"307","author":"Joensuu","year":"2012","journal-title":"JAMA"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"e184060","DOI":"10.1001\/jamaoncol.2018.4060","article-title":"Efficacy and tolerability of 5-year adjuvant imatinib treatment for patients with resected intermediate- or high-risk primary gastrointestinal stromal tumor: the PERSIST-5 clinical trial.","volume":"4","author":"Raut","year":"2018","journal-title":"JAMA Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029411","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T05:01:03Z","timestamp":1746334863000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,12]]},"references-count":35,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000029411","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,12]]}}}